The EC has approved Incyte’s Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or refractory FL.

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

The US Centers for Disease and Prevention (CDC) no longer recommends that all US newborns receive the hepatitis B vaccine, ...

Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...

Cellular Origins is a UK‑based company enabling scalable, factory‑led automation for cell and gene therapy manufacturing, and ...

Large deals in H2 2025 included Novartis’ $12 billion acquisition of Avidity Biosciences and Genmab’s buyout of Merus, ...

Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively. Following the disappointment of a ...

BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...

Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...

US-based private investment company SK Capital Partners’ affiliate is to invest in Swixx BioPharma to support its growth and ...

GSK's Exdensur (depemokimab) is now the first FDA-approved, twice-yearly add-on maintenance therapy for severe eosinophilic asthma.